RT Journal Article
SR Electronic
T1 Protocol for a prospective feasibility study investigating phenoconversion of <em>CYP3A4</em>, <em>CYP2C19</em> and <em>CYP2D6</em> genotypes in paediatric and adolescent and young adult patients with an acute diagnosis of Hodgkin or Non-Hodgkin Lymphoma [PEGASUS]
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.06.04.24308472
DO 10.1101/2024.06.04.24308472
A1 Conyers, Rachel
A1 Stenta, Tayla
A1 Felmingham, Ben
A1 Somogyi, Andrew
A1 Kirkpatrick, Carl
A1 Halman, Andreas
A1 Moore, Claire
A1 Khatri, Dhrita
A1 Williams, Elizabeth
A1 Dyas, Roxanne
A1 Elliott, David A.
A1 Gwee, Amanda
A1 Alexander, Marliese
YR 2024
UL http://medrxiv.org/content/early/2024/06/05/2024.06.04.24308472.abstract
AB Introduction Phenoconversion is the discrepancy between the predicted phenotype based on genotyping (genotype-based phenotype) and the actual phenotype influenced by non-genetic factors (clinical phenotype). Despite its potential impact on drug selection, efficacy, toxicity, and cancer treatment outcomes, research in this area is limited. This study aimed to assess the acceptability and feasibility of investigating phenoconversion using probe medications in a paediatric and adolescent and young adult oncology patient population.Methods and Analysis This prospective, single-arm, partially blinded, non-randomized feasibility study will enrol individuals aged 6-25 with a new diagnosis of Hodgkin Lymphoma or Non-Hodgkin Lymphoma. Genotyping will be performed at baseline using whole genome sequencing or targeted panel testing. Longitudinal phenotyping will be conducted throughout the cancer treatment journey using exogenous oral enzyme-specific probes, specifically subtherapeutic doses of dextromethorphan (CYP2D6) and omeprazole (CYP2C19, CYP3A4) for enzyme activity assessment. The primary outcome measure will be the proportion of patients who consent to the study and successfully complete baseline and at least two longitudinal time points with valid probe drug metabolic ratio measurements. Secondary outcomes include classification of clinical phenotypes based on probe drug metabolic ratios, probe drug safety, barriers to consent, acceptability of pharmacogenomic and phenoconversion testing, longitudinal genotype/phenotype concordance and inflammatory profiles, and investigation of patient and disease factors influencing phenoconversion.Ethics and Dissemination The ethics approval of the trial has been obtained from the Sydney Childrens Ethics Committee (2023/ETH1954). Findings will be disseminated through peer-reviewed publications and professional conference presentations.Trial Registration ClinicalTrials.gov NCT 06383338STRENGTHS AND LIMITATIONS OF THIS STUDYPioneering study: This is the first study to conduct longitudinal phenotype assessments in a paediatric and adolescent and young adult oncology population.Primary outcome focus: The primary outcome includes patient consent and successful longitudinal probe drug derived clinical-phenotype assessments, crucial for designing future clinical trials.Generalisability: Conducting the study within both paediatric and adult hospital systems will enhance generalisability.Blinding: Probe drug metabolic ratio assessments are conducted blinded to genotype.Power: The trial is not powered to assess outcomes of or factors influencing phenoconversion, however secondary outcome evaluations may help prioritise outcomes/factors for further investigation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementPEGASUS is funded through a nationally competitive Medical Research Future Fund Grant (EPCDRI Paediatric Cancer MRF/2007620) as part of the Pharmacogenomics discovery aimAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThis is a protocol paper - so does not include data.